Home > Publications Database > New landscape of the diagnosis of Alzheimer's disease. > print

001     281510
005     20251102002048.0
024 7 _ |a 10.1016/S0140-6736(25)01294-2
|2 doi
024 7 _ |a pmid:40997838
|2 pmid
024 7 _ |a 0140-6736
|2 ISSN
024 7 _ |a 0023-7507
|2 ISSN
024 7 _ |a 1474-547X
|2 ISSN
024 7 _ |a altmetric:181613555
|2 altmetric
037 _ _ |a DZNE-2025-01131
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Frisoni, Giovanni B
|b 0
245 _ _ |a New landscape of the diagnosis of Alzheimer's disease.
260 _ _ |a London [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1761731765_30625
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. Before the advent of biomarkers, post-mortem examination was the only method available to establish a definitive diagnosis. In this first paper of the Series, we review state-of-the-art diagnostic practices and the typical patient journey in specialist settings, where clinicians engage in a differential diagnosis to establish whether Alzheimer's pathology (cerebral deposition of β-amyloid and hyperphosphorylated tau) is a contributor to cognitive impairment. Biomarkers indicating dysregulation of β-amyloid and tau homeostasis, measured with PET and cerebrospinal fluid analysis, allow a molecular-level diagnosis-a mandatory step in defining eligibility for the recently approved anti-amyloid treatments. We anticipate that easily accessible blood biomarkers, already available in some countries, will lead to a new diagnostic revolution and bring about major changes in health-care systems worldwide.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnosis
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a Diagnosis, Differential
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
700 1 _ |a Hansson, Oskar
|b 1
700 1 _ |a Nichols, Emma
|b 2
700 1 _ |a Garibotto, Valentina
|b 3
700 1 _ |a Schindler, Suzanne E
|b 4
700 1 _ |a van der Flier, Wiesje M
|b 5
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 6
|u dzne
700 1 _ |a Villain, Nicolas
|b 7
700 1 _ |a Arenaza-Urquijo, Eider M
|b 8
700 1 _ |a Crivelli, Lucia
|b 9
700 1 _ |a Fortea, Juan
|b 10
700 1 _ |a Grinberg, Lea T
|b 11
700 1 _ |a Ismail, Zahinoor
|b 12
700 1 _ |a Minoshima, Satoshi
|b 13
700 1 _ |a Ossenkoppele, Rik
|b 14
700 1 _ |a Zetterberg, Henrik
|b 15
700 1 _ |a Petersen, Ronald C
|b 16
700 1 _ |a Dubois, Bruno
|b 17
773 _ _ |a 10.1016/S0140-6736(25)01294-2
|g Vol. 406, no. 10510, p. 1389 - 1407
|0 PERI:(DE-600)1476593-7
|n 10510
|p 1389 - 1407
|t The lancet
|v 406
|y 2025
|x 0140-6736
856 4 _ |u https://pub.dzne.de/record/281510/files/DZNE-2025-01131%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281510/files/DZNE-2025-01131.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281510/files/DZNE-2025-01131.pdf?subformat=pdfa
856 4 _ |x pdfa
|u https://pub.dzne.de/record/281510/files/DZNE-2025-01131%20SUP.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281510
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2000032
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a IF >= 90
|0 StatID:(DE-HGF)9990
|2 StatID
|b LANCET : 2022
|d 2024-12-16
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011102
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21